Literature DB >> 32954426

The mechanistic role of alpha-synuclein in the nucleus: impaired nuclear function caused by familial Parkinson's disease SNCA mutations.

Vivian Chen1,2, Malik Moncalvo3,4, Dominic Tringali1,2, Lidia Tagliafierro1,2, Ahila Shriskanda1,2, Ekaterina Ilich3,4, Wendy Dong3,4, Boris Kantor3,4, Ornit Chiba-Falek1,2.   

Abstract

Alpha-synuclein SNCA has been implicated in the etiology of Parkinson's disease (PD); however, the normal function of alpha-synuclein protein and the pathway that mediates its pathogenic effect is yet to be discovered. We investigated the mechanistic role of SNCA in the nucleus utilizing isogenic human-induced pluripotent stem cells-derived neurons from PD patients with autosomal dominant mutations, A53T and SNCA-triplication, and their corresponding corrected lines by genome- and epigenome-editing. Comparisons of shape and integrity of the nuclear envelope and its resistance to stresses found that both mutations result in similar nuclear envelope perturbations that were reversed in the isogenic mutation-corrected cells. Further mechanistic studies showed that SNCA mutation has adverse effects on the nucleus by trapping Ras-related nuclear protein (RAN) and preventing it from transporting key nuclear proteins such as, DNMT3A, for maintaining normal nuclear function. For the first time, we proposed that α-syn interacts with RAN and normally functions in the nucleocytoplasmic transport while exerts its pathogenic effect by sequestering RAN. We suggest that defects in the nucleocytoplasmic transport components may be a general pathomechanistic driver of neurodegenerative diseases.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2020        PMID: 32954426      PMCID: PMC7645704          DOI: 10.1093/hmg/ddaa183

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  70 in total

Review 1.  Nuclear transport, oxidative stress, and neurodegeneration.

Authors:  Vivek P Patel; Charleen T Chu
Journal:  Int J Clin Exp Pathol       Date:  2011-02-28

2.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

3.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal.

Authors:  L Maroteaux; J T Campanelli; R H Scheller
Journal:  J Neurosci       Date:  1988-08       Impact factor: 6.167

4.  Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases.

Authors:  Paula Desplats; Brian Spencer; Elizabeth Coffee; Pruthul Patel; Sarah Michael; Christina Patrick; Anthony Adame; Edward Rockenstein; Eliezer Masliah
Journal:  J Biol Chem       Date:  2011-02-04       Impact factor: 5.157

Review 5.  Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.

Authors:  Anna Villar-Piqué; Tomás Lopes da Fonseca; Tiago Fleming Outeiro
Journal:  J Neurochem       Date:  2015-09-11       Impact factor: 5.372

6.  Multiplication of the SNCA locus exacerbates neuronal nuclear aging.

Authors:  Lidia Tagliafierro; Madison Elena Zamora; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2019-02-01       Impact factor: 6.150

7.  Physiological and pathological roles of LRRK2 in the nuclear envelope integrity.

Authors:  Vered Shani; Hazem Safory; Raymonde Szargel; Ninghan Wang; Tsipora Cohen; Fatimah Abd Elghani; Haya Hamza; Mor Savyon; Inna Radzishevsky; Lihi Shaulov; Ruth Rott; Kah-Leong Lim; Christopher A Ross; Rina Bandopadhyay; Hui Zhang; Simone Engelender
Journal:  Hum Mol Genet       Date:  2019-12-01       Impact factor: 6.150

8.  Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD.

Authors:  Michael E Ward; Alice Taubes; Robert Chen; Bruce L Miller; Chantelle F Sephton; Jeffrey M Gelfand; Sakura Minami; John Boscardin; Lauren Herl Martens; William W Seeley; Gang Yu; Joachim Herz; Anthony J Filiano; Andrew E Arrant; Erik D Roberson; Timothy W Kraft; Robert V Farese; Ari Green; Li Gan
Journal:  J Exp Med       Date:  2014-08-25       Impact factor: 14.307

9.  α-Synuclein enhances histone H3 lysine-9 dimethylation and H3K9me2-dependent transcriptional responses.

Authors:  Naoto Sugeno; Sandra Jäckel; Aaron Voigt; Zinah Wassouf; Julia Schulze-Hentrich; Philipp J Kahle
Journal:  Sci Rep       Date:  2016-11-03       Impact factor: 4.379

Review 10.  The Synucleinopathies: Twenty Years On.

Authors:  Michel Goedert; Ross Jakes; Maria Grazia Spillantini
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

View more
  10 in total

1.  Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies.

Authors:  David J Koss; Daniel Erskine; Andrew Porter; Pawel Palmoski; Hariharan Menon; Olivia G J Todd; Marta Leite; Johannes Attems; Tiago F Outeiro
Journal:  Acta Neuropathol Commun       Date:  2022-07-06       Impact factor: 7.578

Review 2.  CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease.

Authors:  Mujeeb Ur Rahman; Muhammad Bilal; Junaid Ali Shah; Ajeet Kaushik; Pierre-Louis Teissedre; Małgorzata Kujawska
Journal:  Pharmaceutics       Date:  2022-06-13       Impact factor: 6.525

Review 3.  Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives.

Authors:  Tizibt Ashine Bogale; Gaia Faustini; Francesca Longhena; Stefania Mitola; Marina Pizzi; Arianna Bellucci
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

Review 4.  Targeting α-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models.

Authors:  Angeliki Spathopoulou; Frank Edenhofer; Lisa Fellner
Journal:  Front Neurol       Date:  2022-01-25       Impact factor: 4.003

5.  Decoding the Role of Familial Parkinson's Disease-Related Genes in DNA Damage and Repair.

Authors:  Yao-Lin Li; Zhong-Xuan Wang; Chang-Zhou Ying; Bao-Rong Zhang; Jia-Li Pu
Journal:  Aging Dis       Date:  2022-10-01       Impact factor: 9.968

6.  KPNB1 modulates the Machado-Joseph disease protein ataxin-3 through activation of the mitochondrial protease CLPP.

Authors:  Jonasz Jeremiasz Weber; Priscila Pereira Sena; Mahkameh Abeditashi; Ana Velic; Maria Kalimeri; Rana Dilara Incebacak Eltemur; Jana Schmidt; Jeannette Hübener-Schmid; Stefan Hauser; Boris Macek; Olaf Riess; Thorsten Schmidt
Journal:  Cell Mol Life Sci       Date:  2022-07-06       Impact factor: 9.207

Review 7.  Lipid Nanoparticles: Promising Treatment Approach for Parkinson's Disease.

Authors:  Keelan Jagaran; Moganavelli Singh
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

8.  Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse.

Authors:  Yutaka Itokazu; Takahiro Fuchigami; John C Morgan; Robert K Yu
Journal:  Mol Ther       Date:  2021-06-08       Impact factor: 12.910

Review 9.  Neurons and Glia Interplay in α-Synucleinopathies.

Authors:  Panagiota Mavroeidi; Maria Xilouri
Journal:  Int J Mol Sci       Date:  2021-05-08       Impact factor: 5.923

Review 10.  Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives.

Authors:  Wendy Dong; Boris Kantor
Journal:  Viruses       Date:  2021-07-01       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.